Suchergebnisse - "Cui, Yuying"

PubPharm (68)

1

Correction : The effectiveness and safety of bevacizumab versus cetuximab in the treatment of colorectal cancer: a systematic review and meta‑analysis

enthalten in: International journal of clinical pharmacy | 2024

von Cui, Y. | Guo, Y.

ErratumFor: Int J Clin Pharm. 2022 Aug;44(4):843-851. - PMID 35750983

2

Comparative Efficacy and Safety of Tirzepatide in Asians and Non-Asians with Type 2 Diabetes Mellitus : A Systematic Review and Meta-Analysis

enthalten in: Diabetes therapy : research, treatment and education of diabetes and related disorders | 2024

von Cui, Y. | Yao, J. | Qiu, X. | +4

3

Comparative Efficacy and Safety of Tirzepatide in Asians and Non-Asians with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis

enthalten in: Diabetes therapy | 2024

von Cui, Y. | Yao, J. | Qiu, X. | +4

4

Claudin-2 Mediates the Proximal Tubular Epithelial Cell-Fibroblast Crosstalk via Paracrine CTGF

enthalten in: Diabetes, metabolic syndrome and obesity : targets and therapy | 2024

von Guo, C. | Jiao, M. | Cui, Y. | +4

5

Correction: The effectiveness and safety of bevacizumab versus cetuximab in the treatment of colorectal cancer: a systematic review and meta‑analysis

enthalten in: International journal of clinical pharmacy | 2024

von Cui, Y. | Guo, Y.

6

Cardiorenal Benefits of Finerenone in Different Races and Kidney Function in Patients with Chronic Kidney Disease

enthalten in: Cardiorenal medicine | 2024

von Li, P. | Cui, Y. | Xu, X. | +2

7

Vanin1 (VNN1) in chronic diseases : Future directions for targeted therapy

enthalten in: European journal of pharmacology | 2024

von Yu, H. | Cui, Y. | Guo, F. | +5

8

Active oxygen responsive nanogel drug carrier for treating brucella and preparation method of active oxygen responsive nanogel drug carrier

enthalten in: Europäisches Patentamt | 2023

von YANG SHENGCHAO | QIN YUCHANG | LYU XUAN | +7

9

Active oxygen responsive nanogel drug carrier for treating brucella and preparation method of active oxygen responsive nanogel drug carrier

enthalten in: Europäisches Patentamt | 2023

von YANG SHENGCHAO | QIN YUCHANG | LYU XUAN | +7

10

Author Correction to : The effectiveness and safety of bevacizumab versus cetuximab in the treatment of colorectal cancer: a systematic review and meta‑analysis

enthalten in: International journal of clinical pharmacy | 2023

von Cui, Y. | Guo, Y.

ErratumFor: Int J Clin Pharm. 2022 Aug;44(4):843-851. - PMID 35750983

1
2
3
4
5
6
7
Nächster »
[7]